The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial
Uloženo v:
| Název: | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial |
|---|---|
| Autoři: | Tae-Hyun, Yoo, Soon Jun, Hong, Sunggyun, Kim, Seokjoon, Shin, Dong Ki, Kim, Jung Pyo, Lee, Sang Youb, Han, Sangho, Lee, Jong Chul, Won, Young Sun, Kang, Jongha, Park, Byoung-Geun, Han, Ki-Ryang, Na, Kyu Yeon, Hur, Yong-Jin, Kim, Sungha, Park |
| Přispěvatelé: | Tae-Hyun Yoo, Soon Jun Hong, Sunggyun Kim, Seokjoon Shin, Dong Ki Kim, Jung Pyo Lee, Sang Youb Han, Sangho Lee, Jong Chul Won, Young Sun Kang, Jongha Park, Byoung-Geun Han, Ki-Ryang Na, Kyu Yeon Hur, Yong-Jin Kim, Sungha Park, Park, Sung Ha |
| Zdroj: | Hypertension Research. 45:2008-2017 |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2022. |
| Rok vydání: | 2022 |
| Témata: | Losartan / therapeutic use, Albuminuria / etiology, Renal endpoint, Antihypertensive Agents / therapeutic use, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Diabetic nephropathy, Losartan, Proteinuria / etiology, Angiotensin Receptor Antagonists, 03 medical and health sciences, Hypertension, 0302 clinical medicine, Double-Blind Method, Angiotensin Receptor Antagonists / pharmacology, Diabetes Mellitus, Humans, Albuminuria, Diabetic Nephropathies, Renal Insufficiency, Mortality, Renal Insufficiency, Chronic, Antihypertensive Agents, Angiotensin-Converting Enzyme Inhibitors / pharmacology, Chronic* / complications, Diabetic Nephropathies* / drug therapy, 3. Good health, Losartan / pharmacology, Proteinuria, Chronic* / drug therapy, Albuminuria / chemically induced, Proteinuria / drug therapy |
| Popis: | As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD. This was a randomized, multicenter, double-blind, 4-parallel-group, dose-titration, phase III study designed to compare the efficacy of fimasartan and losartan in reducing albuminuria in patients with DKD (NCT02620306). The primary endpoint was the rate of change in albuminuria from baseline to week 24. A total of 341 patients were randomized to different groups. The urinary albumin-to-creatinine ratio (ACR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were not different between the fimasartan and losartan groups at baseline (ACR: 1376.84 vs. 1521.07 mg/gCr, SBP: 154.69 vs. 154.47 mmHg, DBP: 83.96 vs. 83.83 mmHg). However, ACR reduction was significantly larger in the fimasartan group than in the losartan group during the entire study period (% changes in the ACR at 4, 8, 12, and 24 weeks were -23.58, -33.06, -35.00, and -38.13 in the fimasartan group vs. -8.74, -10.17, -14.91, and -19.71 in the losartan group, p |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 1348-4214 0916-9636 |
| DOI: | 10.1038/s41440-022-01028-6 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/36123398 |
| Rights: | Springer TDM CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....9e5b173743ab0d0ebc1f92c62849c1ec |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD. This was a randomized, multicenter, double-blind, 4-parallel-group, dose-titration, phase III study designed to compare the efficacy of fimasartan and losartan in reducing albuminuria in patients with DKD (NCT02620306). The primary endpoint was the rate of change in albuminuria from baseline to week 24. A total of 341 patients were randomized to different groups. The urinary albumin-to-creatinine ratio (ACR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were not different between the fimasartan and losartan groups at baseline (ACR: 1376.84 vs. 1521.07 mg/gCr, SBP: 154.69 vs. 154.47 mmHg, DBP: 83.96 vs. 83.83 mmHg). However, ACR reduction was significantly larger in the fimasartan group than in the losartan group during the entire study period (% changes in the ACR at 4, 8, 12, and 24 weeks were -23.58, -33.06, -35.00, and -38.13 in the fimasartan group vs. -8.74, -10.17, -14.91, and -19.71 in the losartan group, p |
|---|---|
| ISSN: | 13484214 09169636 |
| DOI: | 10.1038/s41440-022-01028-6 |